Reasons for leaving out were patient unwillingness to participate in the study (n = 8), normalization of ALT during the lead-in phase (n = 6), autoimmune hepatitis (n = 1), and viral hepatitis (n = 1) (Step 2). This evidence concerns the gene GPT and autoimmune hepatitis.